Diana Osorio
Department of Pediatrics, Division of Pediatrics
About Dr. Diana Osorio
Present Title & Affiliation
Primary Appointment
Inpatient Medical Director, Department of Pediatrics - Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas
Center Medical Director, Department of Pediatrics - Patient Care, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor, Department of Pediatrics - Patient Care, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Patient Care, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2007 | Universidad Central del Caribe, Puerto Rico, Bayamón, Puerto Rico, US, MD |
Postgraduate Training
| 2013-2014 | Postgraduate Fellow, Neuro-Oncology, New York University Langone Medical Center, New York, New York |
| 2010-2013 | Postgraduate Fellow, Hematology/Oncology, Northwell Health- Cohen Children’s Medical Center, New Hyde Park, New York |
| 2007-2010 | Resident, Pediatrics, Northwell Health- Cohen Children’s Medical Center, New Hyde Park, New York |
Licenses & Certifications
| 2025 | Florida Board of Medicine |
| 2024 | Texas License |
| 2021 | American Board of Pediatrics Hematology Oncology |
| 2017 | American Board of Pediatrics |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Pediatrics, The Ohio State University, Colombus, Ohio, 2014 - 2021
Other Professional Positions
Member, Society for Neuro-Oncology, MD Anderson Cancer Center, 2020 - Present
Member, Society for Neuro-Oncology, Nationwide Children's, 2013 - Present
Extramural Institutional Committee Activities
Member, MD Anderson IRB, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Member, Pediatric Clinical Practice Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Pediatric Brain Tumor Consortium (PBTC) Ependymoma and Immunotherapy Committee, Nationwide Children's Hospital, 2020 - 2021
Member, Pacific Pediatric Neuro-Oncology Consortium (PNOC) CNS Germ Cell Tumor Working Group, Pediatric Neuro-Oncology Consortium, 2020 - 2021
Member, AACR-PLGAF Pediatric Brain Tumor Research Grants Scientific Review Committee, Nationwide Children's Hospital, 2019 - 2021
Member, Team Hope, Nationwide Children's Hospital, 2016 - 2021
Member, CSRC, Nationwide Children's Hospital, 2016 - 2021
Editorial Activities
Journal Reviewer, Neuro Oncology Pediatrics, 2024 - Present
Topic Editor, Frontiers in Oncology, 2023 - Present
Journal Reviewer, Cancer Reports, 2021 - Present
Journal Reviewer, Oncology research and treatment, 2020 - Present
Journal Reviewer, Journal Pediatric Hematology Oncology, 2020 - Present
Journal Reviewer, Child Nervous System, 2019 - Present
Journal Reviewer, Cancer, 2018 - Present
Journal Reviewer, Pediatric Blood and Cancer, 2017 - 2021
Journal Reviewer, Pediatric Neurology, 2014 - 2018
Honors & Awards
| 2023 - Present | Think Tank: Genetic Predisposition to Primary CNS Cancers |
Selected Presentations & Talks
Local Presentations
- 2024. “Brain Tumors in Neurofibromatosis”. Invited. Texas Neurofibromatosis Foundation Symposium. Houston, Texas, US.
- 2024. Peds Neuro Onc future clinical trials at MDA. Invited. Energy Transfer’s Fundraising Campaign Event. Houston, Texas, US.
Regional Presentations
- 2025. PNOC033 Study Updates. Pediatric Neuro Oncology Consortium, US.
International Presentations
- 2025. Neuro-Oncologia Pediatrica: Generalidades y Trabajo en Equipo. Invited, CR.
- 2025. Very Long-Term Survival in Patients with Recurrent Central Nervous System (CNS) Germ Cell Tumors (GCT). Poster. International CNS-GCT Conference, US.
- 2025. Choroid Plexus Carcinoma Molecularly-Risk Stratified Treatment Strategy. Invited. VIVA-Asia Rare Tumor Board #17: Infant Brain Tumors – Choroid Plexus, SG.
- 2025. Central Nervous System Tumors Session, Updates on Ependymoma. Invited. 36th SLAOP Annual Meeting and 23rd ACHOP Annual Meeting, US.
- 2024. Management of Germ Cell Tumors in Pediatric Patients. Invited. 42nd National and 11th International Congress of Oncology of the Mexican Society of Oncology, US.
- 2023. Pediatric Neuro-oncology in the New Molecular Era. Invited. Mexican Association of Pediatric OncoHematology (AMOHP), US.
- 2021. Medulloblastoma Treatment Guidelines in Central America. Invited. 23rd annual Association of Pediatric Hematology Oncology in Central America, US.
- 2020. Addressing Global and Loco-Regional Disparities in the Management of Childhood Brain Cancer. Invited. Pediatric Grand Rounds Nationwide Children’s Hospital.
- 2020. Directed Medulloblastoma Treatment Guidelines in Central America. Invited. 22nd annual Association of Pediatric Hematology Oncology in Central America, US.
- 2019. Management of Infant and Childhood Medulloblastoma and the Management of Ependymoma. Invited. 8th Annual Latin American Pediatric Neurosurgery Conference, US.
- 2018. Pediatric Neuro-Oncology Pertinent to Low-to-Middle Income Countries (LMIC). Invited. Co-organizing committee member and 3rd PLANO educational conference at INEN, US.
- 2018. Association of Pediatric Hematology/Oncology of Colombia (ACHOP), Regional conference. Ependymoma and Medulloblastoma. Invited, US.
- 2018. Management of Medulloblastoma, Craniopharyngioma and Central Nervous System Germ Cell Tumors. Leo Messi Foundation Neuro-oncology Course. Invited, US.
- 2017. Experiencia de un grupo de discusión interactivo Latino Americano en tumores del SNC. Latin American Society of Pediatric Oncology (SLAOP). Invited, US.
- 2016. Pediatric Brain Tumors Session, Session Organizer and Moderator: Pediatric Brain Tumor Patient Cases and Discussion of their Management, Association of Pediatric Hematology/Oncology Central America. Invited, US.
- 2015. First International Pediatric Latin American Neurooncology (PLANO) at GRACC Institute; Management of Low Grade Gliomas and Management of ATRT/PNET. Invited, US.
- 2013. Dasatinib in children and adolescents with central nervous system germ cell tumors. Poster. Third International CNS Germ Cell Tumor Symposium, US.
- 2013. Prevalence of elevated erythrocyte adenosine deaminase activity, a marker for Diamond Blackfan Anemia in patients with congenital heart disease. Poster. American Society of Peditaric Hematology Oncology, US.
- 2009. Irradiation-avoiding strategies in the management of young children with newly diagnosed central nervous system embryonal tumors: 18 years of three serial chemotherapy regimens – the “Head Start” Protocols. Invited. Thirty-fifth Annual Meeting of the Korean Cancer Society, US.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy |
| Funding Source: | Eli Lilly |
| Role: | PI |
| Date: | 2025 - Present |
| Title: | DIPG/DMG Psychosocial Support: Grief-informed interventions to bolster meaning and reduce emotional distress |
| Funding Source: | Children's Brain Tumor Foundation |
| Role: | PI |
| Date: | 2024 - Present |
| Title: | A Phase I clinical trial with a window-of-opportunity component of engineered NK cells containing deleted TGF-βR2 and NR3C1 in recurrent grade 4 astrocytoma (glioblastoma) |
| Funding Source: | SPORE |
| Role: | Co-PI |
| ID: | Protocol Number: 2020-0960 |
| Date: | 2024 - Present |
| Title: | (PNOC-033) Molecular Risk-Adapted Therapy for Newly Diagnosed Choroid Plexus Carcinoma in Children and Young Adults |
| Funding Source: | Philanthropy |
| Role: | PI |
| Date: | 2024 - Present |
| Title: | Phase II Trial Evaluating Chemotherapy Followed by Response- Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas |
| Funding Source: | COG |
| Role: | Co-PI |
| ID: | ACNS2321 |
| Date: | 2024 - Present |
| Title: | Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations |
| Funding Source: | NCI |
| Role: | Co-PI |
| ID: | ACNS1931 |
Selected Publications
Peer-Reviewed Articles
- Osorio DS, Yankelevich M, Zaky WT, Lafay-Cousin L, Margol AS, Toll S, Quiroz L, Fox JE, Hanson D, Gardner SL, Prados M, Mueller S, L Finlay AJ. Marrow-ablative consolidation chemotherapy (HDCT) to decrease the development of choroid plexus carcinoma (CPC) specific relapse in high-risk TP53-mutated (germline or somatic) young children with newly diagnosed CPC. JCO 42(16), 2024. e-Pub 2024.
Review Articles
- Osorio DS, Yankelevich M, Lafay-Cousin L, Zaky W. An overview of the diagnosis and management of Choroid Plexus tumors. Adv Cancer Res 167:103-139, 2025. e-Pub 2025. PMID: 41198335.
Other Articles
- Osorio, Finlay JL, Dhall G, Goldman S, Eisenstat D, Brown RJ Feasibility of dasatinib in children and adolescents with newly-diagnosed or recurrent CNS Germ Cell Tumors. Pediatr Blood Cancer 60(9):E100-102, 2013. PMID: 23754592.
Editorials
- Osorio, DS, Qaddoumi, I, Moreira, DC. Editorial: Pediatric CNS tumors in low- and middle-income countries: expanding our understanding. Frontiers in Oncology 15, 2025. PMID: 39931086.
Patient Reviews
CV information above last modified January 12, 2026